ADC THERAPEUTICS SA news, videos and press releases
For more news please use our advanced search feature.
ADC THERAPEUTICS SA - More news...
ADC THERAPEUTICS SA - More news...
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics to Present at Upcoming Investor Conferences
- ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
- ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
- ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
- ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
- ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
- ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
- ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
- ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
- ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
- ADC Therapeutics Provides Business Updates
- ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
- ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
- ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
